Summit opens new front for ivonescimab, challenging durvalumab after chemoradiation in lung cancer
Summit Therapeutics has begun a late-stage trial pitting its lead drug against durvalumab in unresectable Stage III lung cancer, but has not disclosed size, dosing or timelines.
Summit Therapeutics has started a third-party-comparator trial for its lead asset: on 18 November 2026 it announced the launch of HARMONi-10, a Phase III study that sets ivonescimab directly against durvalumab in patients with unresectable, locally advanced Stage III non-small cell lung cancer. The company says the study could be used to support registration.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Company's press release (SEC filing): Summit Therapeutics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.